Lamivudine (BioDeep_00000405880)

Main id: BioDeep_00000002765

 


代谢物信息卡片


4-Amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone

化学式: C8H11N3O3S (229.0521)
中文名称: 4-氨基-1-[(2R,5S)-2-(羟基甲基)-1,3-氧硫杂环戊-5-基]-2(1H)-嘧啶酮, 拉米夫定, ENT-拉米夫定
谱图信息: 最多检出来源 Homo sapiens(urine) 25%

分子结构信息

SMILES: C1C(OC(S1)CO)N2C=CC(=NC2=O)N
InChI: InChI=1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1

描述信息

J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals > J05AF - Nucleoside and nucleotide reverse transcriptase inhibitors
C471 - Enzyme Inhibitor > C1589 - Reverse Transcriptase Inhibitor > C97452 - Nucleoside Reverse Transcriptase Inhibitor
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D018894 - Reverse Transcriptase Inhibitors
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents
D009676 - Noxae > D000963 - Antimetabolites > D015224 - Dideoxynucleosides
D004791 - Enzyme Inhibitors > D019384 - Nucleic Acid Synthesis Inhibitors
C254 - Anti-Infective Agent > C281 - Antiviral Agent
CONFIDENCE standard compound; INTERNAL_ID 903; DATASET 20200303_ENTACT_RP_MIX500; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 1726; ORIGINAL_PRECURSOR_SCAN_NO 1725
CONFIDENCE standard compound; INTERNAL_ID 903; DATASET 20200303_ENTACT_RP_MIX500; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 1732; ORIGINAL_PRECURSOR_SCAN_NO 1730
CONFIDENCE standard compound; INTERNAL_ID 903; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 1745; ORIGINAL_PRECURSOR_SCAN_NO 1743
CONFIDENCE standard compound; INTERNAL_ID 903; DATASET 20200303_ENTACT_RP_MIX500; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 1734; ORIGINAL_PRECURSOR_SCAN_NO 1733
CONFIDENCE standard compound; INTERNAL_ID 903; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 1740; ORIGINAL_PRECURSOR_SCAN_NO 1736
CONFIDENCE standard compound; INTERNAL_ID 903; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 1743; ORIGINAL_PRECURSOR_SCAN_NO 1741
Lamivudine (BCH-189) is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Lamivudine can inhibit HIV reverse transcriptase 1/2 and also the reverse transcriptase of hepatitis B virus. Lamivudine salicylate can penetrate the CNS[1][2].

同义名列表

6 个代谢物同义名

4-Amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone; Lamivudine; 2,3-Dideoxy-3-thiacytidine; ent-Lamivudine; BCH-189; Lamivudine



数据库引用编号

30 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表
Cytoplasm 6 ABCB1, ADRA2A, AFP, ALB, CCR5, DCK
Endosome membrane 1 HLA-B
Endoplasmic reticulum membrane 3 CD4, HLA-B, MIA3
Mitochondrion membrane 1 ABCG2
Nucleus 2 ALB, DCK
cytosol 3 ALB, DCK, GPT
mitochondrial membrane 1 ABCG2
centrosome 1 ALB
nucleoplasm 3 ABCG2, DCK, MS4A1
Cell membrane 9 ABCB1, ABCG2, ADRA2A, CCR5, CD4, HLA-B, MS4A1, SLC22A1, TNF
Lipid-anchor 1 MS4A1
Early endosome membrane 1 HLA-B
Multi-pass membrane protein 7 ABCB1, ABCG2, ADRA2A, CCR5, MS4A1, SLC22A1, SLC22A2
cell surface 5 ABCB1, CCR5, HLA-B, MS4A1, TNF
glutamatergic synapse 1 ADRA2A
Golgi apparatus 2 ALB, HLA-B
Golgi membrane 2 HLA-B, INS
lysosomal membrane 1 HLA-B
neuronal cell body 2 ADRA2A, TNF
Presynapse 2 SLC22A1, SLC22A2
endosome 1 CCR5
plasma membrane 11 ABCB1, ABCG2, ADRA2A, CCR5, CD4, HLA-B, IFNLR1, MS4A1, SLC22A1, SLC22A2, TNF
Membrane 9 ABCB1, ABCG2, CCR5, HLA-B, IFNLR1, MIA3, MS4A1, SLC22A1, SLC22A2
apical plasma membrane 4 ABCB1, ABCG2, SLC22A1, SLC22A2
basolateral plasma membrane 3 ADRA2A, SLC22A1, SLC22A2
extracellular exosome 6 ABCB1, ALB, GPT, HLA-B, MS4A1, SLC22A2
Lysosome membrane 1 HLA-B
endoplasmic reticulum 2 ALB, HLA-B
extracellular space 7 AFP, ALB, HLA-B, IFNA1, INS, MS4A1, TNF
mitochondrion 1 DCK
protein-containing complex 1 ALB
intracellular membrane-bounded organelle 1 MIA3
Single-pass type I membrane protein 3 CD4, HLA-B, IFNLR1
Secreted 4 AFP, ALB, IFNA1, INS
extracellular region 3 ALB, INS, TNF
Single-pass membrane protein 2 HLA-B, MIA3
anchoring junction 1 ALB
external side of plasma membrane 5 CCR5, CD4, HLA-B, MS4A1, TNF
Early endosome 1 CD4
recycling endosome 1 TNF
Single-pass type II membrane protein 1 TNF
presynaptic active zone membrane 1 ADRA2A
Apical cell membrane 4 ABCB1, ABCG2, SLC22A1, SLC22A2
Membrane raft 3 ABCG2, CD4, TNF
GABA-ergic synapse 1 ADRA2A
lateral plasma membrane 1 SLC22A1
receptor complex 1 ADRA2A
ciliary basal body 1 ALB
phagocytic cup 1 TNF
phagocytic vesicle membrane 1 HLA-B
centriole 1 ALB
brush border membrane 1 ABCG2
spindle pole 1 ALB
blood microparticle 1 ALB
Basolateral cell membrane 2 SLC22A1, SLC22A2
Recycling endosome membrane 1 HLA-B
endosome lumen 1 INS
basal plasma membrane 2 SLC22A1, SLC22A2
plasma membrane raft 1 MS4A1
secretory granule lumen 1 INS
secretory granule membrane 1 HLA-B
Golgi lumen 1 INS
endoplasmic reticulum lumen 5 AFP, ALB, CD4, INS, MIA3
platelet alpha granule lumen 1 ALB
axon terminus 1 ADRA2A
transport vesicle 1 INS
Endoplasmic reticulum-Golgi intermediate compartment membrane 1 INS
endoplasmic reticulum exit site 1 MIA3
postsynaptic density membrane 1 ADRA2A
ER to Golgi transport vesicle membrane 1 HLA-B
clathrin-coated endocytic vesicle membrane 1 CD4
Basal cell membrane 2 SLC22A1, SLC22A2
Lateral cell membrane 1 SLC22A1
external side of apical plasma membrane 2 ABCB1, ABCG2
lumenal side of endoplasmic reticulum membrane 1 HLA-B
dopaminergic synapse 1 ADRA2A
[Tumor necrosis factor, soluble form]: Secreted 1 TNF
T cell receptor complex 1 CD4
MHC class I protein complex 1 HLA-B
MHC class II protein complex 1 HLA-B
ciliary transition fiber 1 ALB
interleukin-28 receptor complex 1 IFNLR1
[C-domain 2]: Secreted 1 TNF
[Tumor necrosis factor, membrane form]: Membrane 1 TNF
[C-domain 1]: Secreted 1 TNF


文献列表

  • Elisa de Lazzari, Eugenia B Negredo, Pere Domingo, Juan M Tiraboschi, Esteve Ribera, Nadia Abdulghani, Verònica Alba, Salvador Fernández-Arroyo, Consuelo Viladés, Joaquim Peraire, Jose M Gatell, Jose L Blanco, Francesc Vidal, Anna Rull, Esteban Martinez. Multiomics plasma effects of switching from triple antiretroviral regimens to dolutegravir plus lamivudine. The Journal of antimicrobial chemotherapy. 2024 May; 79(5):1133-1141. doi: 10.1093/jac/dkae083. [PMID: 38546974]
  • Sergio Sequera-Arquelladas, Carmen Hidalgo-Tenorio, Luis López-Cortés, Alicia Gutiérrez, Jesús Santos, Francisco Téllez, Mohamed Omar, Sergio Ferra-Murcia, Elisa Fernández, Rosario Javier, Coral García-Vallecillos, Juan Pasquau. DOLAMA 200: Effectiveness and Safety of a Dual Therapy with Dolutegravir Plus Lamivudine in Treatment-Experienced HIV-1 Infected Real World Participants in Spain. Viruses. 2024 02; 16(2):. doi: 10.3390/v16020259. [PMID: 38400035]
  • Chloe Orkin, Jean-Michel Molina, Pedro Cahn, Johannes Lombaard, Khuanchai Supparatpinyo, Sushma Kumar, Havilland Campbell, Hong Wan, Valerie Teal, Zhi Jin Xu, Ernest Asante-Appiah, Peter Sklar, Hedy Teppler, Rima Lahoulou. Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials. The lancet. HIV. 2024 Feb; 11(2):e75-e85. doi: 10.1016/s2352-3018(23)00258-8. [PMID: 38141637]
  • Abigail Wong, Yenju Chu, Haojie Chen, Wanshan Feng, Liuhang Ji, Chaolong Qin, Michael J Stocks, Maria Marlow, Pavel Gershkovich. Distribution of lamivudine into lymph node HIV reservoir. International journal of pharmaceutics. 2023 Dec; 648(?):123574. doi: 10.1016/j.ijpharm.2023.123574. [PMID: 37935311]
  • Yinghua Wei, Jin Li, Ruhong Xu, Li Wen, Yiming Deng, Lixia He, Huijun Zhong, Yanhao Wang. Efficacy and safety profiles of dolutegravir plus lamivudine vs. bictegravir/emtricitabine/tenofovir alafenamide in therapy-naïve adults with HIV-1. Chinese medical journal. 2023 Nov; ?(?):. doi: 10.1097/cm9.0000000000002907. [PMID: 37914678]
  • Filippo Lagi, Andrea Giacomelli, Vanni Borghi, Arturo Ciccullo, Lucia Taramasso, Giordano Madeddu, Gabriella D'Ettorre, Andrea Giacometti, Filippo Ducci, Andrea De Vito, Rachele Pincino, Simona Di Giambenedetto, Cristina Mussini, Spinello Antinori, Gaetana Sterrantino. Efficacy and tolerability of dolutegravir/lamivudine versus dolutegravir/rilpivirine in switching from a three-drug regimen based on nonnucleoside reverse transcriptase inhibitors: A retrospective cohort study. Journal of medical virology. 2023 10; 95(10):e29149. doi: 10.1002/jmv.29149. [PMID: 37805832]
  • Sandra Rotea-Salvo, Víctor Giménez-Arufe, Alejandro Martínez-Pradeda, Carla Fernández-Oliveira, Álvaro Mena-de-Cea, Luis Margusino-Framiñán, Isabel Martín-Herranz, Purificación Cid-Silva. Lipid profile changes associated with antiretroviral therapies in a real-world cohort. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 2023 Sep; 47(5):T210-T217. doi: 10.1016/j.farma.2023.07.005. [PMID: 37673703]
  • Simone Perazzolo, Zachary Stephen, Masa Eguchi, Xiaolin Xu, Rachele Delle Fratte, Ann C Collier, Ann J Melvin, Rodney J Y Ho. A novel formulation enabled transformation of 3 HIV drugs tenofovir-lamivudine-dolutegravir (TLD) from short-acting to long-acting all-in-one injectable. AIDS (London, England). 2023 Aug; ?(?):. doi: 10.1097/qad.0000000000003706. [PMID: 37650755]
  • Leonardo Calza, Vincenzo Colangeli, Giulia Pensalfine, Lucia Appolloni, Salvatore Vitale, Isabella Bon, Pierluigi Viale. Doravirine/lamivudine/tenofovir disoproxil fumarate in virologically suppressed people living with HIV: A real-life experience. International journal of STD & AIDS. 2023 Aug; ?(?):9564624231195084. doi: 10.1177/09564624231195084. [PMID: 37565832]
  • Sandra Rotea-Salvo, Víctor Giménez-Arufe, Alejandro Martínez-Pradeda, Carla Fernández-Oliveira, Álvaro Mena-de-Cea, Luis Margusino-Framiñán, Isabel Martín-Herranz, Purificación Cid-Silva. Lipid profile changes associated with antiretroviral therapies in a real-world cohort. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 2023 Jun; ?(?):. doi: 10.1016/j.farma.2023.04.007. [PMID: 37349200]
  • Elizabeth Holton, Carla Louw, Edward Archer, Tobias Louw, Gideon Wolfaardt, Barbara Kasprzyk-Hordern. Quantifying community-wide antibiotic usage via urban water fingerprinting: Focus on contrasting resource settings in South Africa. Water research. 2023 May; 240(?):120110. doi: 10.1016/j.watres.2023.120110. [PMID: 37247434]
  • Alejandro D Bendala-Estrada, Mariana Diaz-Almiron, Carmen Busca, Rafael Mican, Julen Cadiñanos, Maria Luisa Montes, Luz Martin-Carbonero, Eulalia Valencia, Rocío Montejano, Ana Delgado-Hierro, Jose I Bernardino. Change in metabolic parameters after switching from triple regimens with tenofovir alafenamide to dolutegravir-based dual therapy. Bi-lipid study. HIV medicine. 2023 05; 24(5):558-567. doi: 10.1111/hiv.13432. [PMID: 36394195]
  • Adem Simsek, Oguz Karabay, Ertugrul Guclu, Hande Toptan. Comparison of Metabolic Effects of Three Different Treatment Combinations with Retrospective Real-life Data in People Living with HIV. Current HIV research. 2023; 21(5):314-322. doi: 10.2174/011570162x266922231107094649. [PMID: 37990894]
  • Eisuke Adachi, Kazuhiko Ikeuchi, Michiko Koga, Hiroshi Yotsuyanagi. Changes in Inflammatory Biomarkers When Switching from Three-Drug Regimens to Dolutegravir Plus Lamivudine in People Living with HIV. AIDS research and human retroviruses. 2022 12; 38(12):881-883. doi: 10.1089/aid.2022.0115. [PMID: 36301933]
  • M A Hamed, R E Akhigbe, A O Aremu, A F Odetayo. Zinc normalizes hepatic lipid handling via modulation of ADA/XO/UA pathway and caspase 3 signaling in highly active antiretroviral therapy-treated Wistar rats. Chemico-biological interactions. 2022 Dec; 368(?):110233. doi: 10.1016/j.cbi.2022.110233. [PMID: 36309141]
  • Francesca Lombardi, Simone Belmonti, Davide Moschese, Massimiliano Fabbiani, Alberto Borghetti, Arturo Ciccullo, Elena Visconti, Simona Di Giambenedetto. Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting. HIV research & clinical practice. 2022 12; 23(1):28-36. doi: . [PMID: 35758043]
  • Liqin Sun, Yun He, Liumei Xu, Fang Zhao, Yang Zhou, Lukun Zhang, Qiaoli Peng, Haitao Zhang, Qiuyue Zhang, Tingzhi Cao, Ying Song, Siyuan Wang, Man Rao, Xinyun Jia, Xiaoning Liu, Jing Zhou, Bin Ju, Hui Wang, Jiaye Liu. Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China. Journal of acquired immune deficiency syndromes (1999). 2022 10; 91(S1):S8-S15. doi: 10.1097/qai.0000000000003040. [PMID: 36094509]
  • Olayemi Osiyemi, Stéphane De Wit, Faïza Ajana, Fiona Bisshop, Joaquín Portilla, Jean Pierre Routy, Christoph Wyen, Mounir Ait-Khaled, Peter Leone, Keith A Pappa, Ruolan Wang, Jonathan Wright, Nisha George, Brian Wynne, Michael Aboud, Jean van Wyk, Kimberly Y Smith. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2022 09; 75(6):975-986. doi: 10.1093/cid/ciac036. [PMID: 35079789]
  • Qianqian Zhang, Youmei Peng, Jiao Hou, Yanhong Chen, Bingjie Liu, Pinghu Zhang, Wenquan Yu, Junbiao Chang. An O-Benzyl Phosphonamidate Prodrug of Tenofovir for the Treatment of Hepatitis B Virus Infection. Journal of medicinal chemistry. 2022 07; 65(13):9493-9505. doi: 10.1021/acs.jmedchem.2c00869. [PMID: 35776695]
  • José L Blanco, Jhon Rojas, Elisa de Lazzari, Alexy Inciarte, Mar Subirana, Pilar Callau, María Martinez-Rebollar, Montserrat Laguno, Josep Mallolas, Lorena de la Mora, Berta Torres, Ana Gonzalez-Cordón, Esteban Martinez. Simplification from tenofovir disoproxil fumarate plus lamivudine or emtricitabine plus ritonavir-boosted protease inhibitor to ritonavir-boosted atazanavir plus lamivudine in virologically suppressed HIV-infected adults with osteopenia: a pilot study. The Journal of antimicrobial chemotherapy. 2022 06; 77(7):1974-1979. doi: 10.1093/jac/dkac137. [PMID: 35512339]
  • Lem Edith Abongwa, Anthony Kebira Nyamache, Fokunang Charles, Judith Torimiro, Nshom Emmanuel, Irénée Domkam, Mbu Eyongetah, Beriyuy Jude, Fung Holgar Mua, Sama Bella, Tankou Colman Tamboh, Erna Charlene Moungang, Victorine Ngum, Paul Okemo. Risk factors of severe hepatotoxicity among HIV-1 infected individuals initiated on highly active antiretroviral therapy in the Northwest Region of Cameroon. BMC gastroenterology. 2022 Jun; 22(1):286. doi: 10.1186/s12876-022-02305-x. [PMID: 35658835]
  • Nicholas I Paton, Joseph Musaazi, Cissy Kityo, Stephen Walimbwa, Anne Hoppe, Apolo Balyegisawa, Jesca Asienzo, Arvind Kaimal, Grace Mirembe, Abbas Lugemwa, Gilbert Ategeka, Margaret Borok, Henry Mugerwa, Abraham Siika, Eva Laker A Odongpiny, Barbara Castelnuovo, Agnes Kiragga, Andrew Kambugu. Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial. The lancet. HIV. 2022 06; 9(6):e381-e393. doi: 10.1016/s2352-3018(22)00092-3. [PMID: 35460601]
  • Gentille Musengimana, Elysee Tuyishime, Athanase Kiromera, Samuel S Malamba, Augustin Mulindabigwi, Madjid R Habimana, Cyprien Baribwira, Muhayimpundu Ribakare, Savio D Habimana, Josh DeVos, Richard C N Mwesigwa, Eugenie Kayirangwa, Jules M Semuhore, Gallican N Rwibasira, Amitabh B Suthar, Eric Remera. Acquired HIV drug resistance among adults living with HIV receiving first-line antiretroviral therapy in Rwanda: A cross-sectional nationally representative survey. Antiviral therapy. 2022 06; 27(3):13596535221102690. doi: 10.1177/13596535221102690. [PMID: 35593031]
  • Boris Revollo, Laura Viñuela, Lorena de la Mora, Federico García, Marc Noguera-Julián, Mariona Parera, Roger Paredes, Josep M Llibre. Integrase resistance emergence with dolutegravir/lamivudine with prior HIV-1 suppression. The Journal of antimicrobial chemotherapy. 2022 05; 77(6):1738-1740. doi: 10.1093/jac/dkac082. [PMID: 35274144]
  • Adewale Oluwaseun Fadaka, Raphael Taiwo Aruleba, Nicole Remaliah Samantha Sibuyi, Ashwil Klein, Abram Madimabe Madiehe, Mervin Meyer. Inhibitory potential of repurposed drugs against the SARS-CoV-2 main protease: a computational-aided approach. Journal of biomolecular structure & dynamics. 2022 05; 40(8):3416-3427. doi: 10.1080/07391102.2020.1847197. [PMID: 33200673]
  • Hui Kong, Hongran Zhao, Tianran Chen, Yanling Song, Yan Cui. Targeted P2X7/NLRP3 signaling pathway against inflammation, apoptosis, and pyroptosis of retinal endothelial cells in diabetic retinopathy. Cell death & disease. 2022 04; 13(4):336. doi: 10.1038/s41419-022-04786-w. [PMID: 35410316]
  • Lucy Campbell, Fowzia Ibrahim, Birgit Barbini, Amanda Samarawickrama, Chloe Orkin, Julie Fox, Laura Waters, Yvonne Gilleece, Shema Tariq, Frank A Post. Bone mineral density, kidney function and participant-reported outcome measures in women who switch from tenofovir disoproxil emtricitabine and a nonnucleoside reverse transcriptase inhibitor to abacavir, lamivudine and dolutegravir. HIV medicine. 2022 04; 23(4):362-370. doi: 10.1111/hiv.13215. [PMID: 34866304]
  • Leonardo Calza, Giorgio Legnani, Ciro Fulgaro, Gabriella Verucchi, Isabella Bon, Tiziana Lazzarotto, Pierluigi Viale. Changes in Serum Inflammatory Markers in Antiretroviral Therapy-Naive HIV-Infected Patients Starting Dolutegravir/Lamivudine or Dolutegravir/Lamivudine/Abacavir. Journal of acquired immune deficiency syndromes (1999). 2022 03; 89(3):e30. doi: 10.1097/qai.0000000000002861. [PMID: 34743087]
  • Sergio Serrano-Villar, María Rosa López-Huertas, Daniel Jiménez, Carlos Galera, Javier Martínez-Sanz, Elena Moreno, Alfonso Muriel, Félix Gutiérrez, Carmen Busca, Joaquín Portilla, Otilia Bisbal, José Antonio Iribarren, Francisco Tejerina, Ignacio de Los Santos, Santiago Moreno. Long-Term Changes of Inflammatory Biomarkers in Individuals on Suppressive Three-Drug or Two-Drug Antiretroviral Regimens. Frontiers in immunology. 2022; 13(?):848630. doi: 10.3389/fimmu.2022.848630. [PMID: 35359950]
  • Rosa Marlene Cuco, Osvaldo Loquiha, Adelino Juga, Aleny Couto, Bindiya Meggi, Adolfo Vubil, Esperança Sevene, Nafissa Osman, Marleen Temermam, Olivier Degomme, Mohsin Sidat, Nilesh Bhatt. Nevirapine hair and plasma concentrations and HIV-1 viral suppression among HIV infected ante-partum and post-partum women attended in a mother and child prevention program in Maputo city, Mozambique. PloS one. 2022; 17(2):e0261522. doi: 10.1371/journal.pone.0261522. [PMID: 35143515]
  • Cameron Hogarth, Keith Arnold, Andrew McLauchlin, Steve P Rannard, Marco Siccardi, Tom O McDonald. Evaluating the impact of systematic hydrophobic modification of model drugs on the control, stability and loading of lipid-based nanoparticles. Journal of materials chemistry. B. 2021 12; 9(48):9874-9884. doi: 10.1039/d1tb02297k. [PMID: 34870664]
  • Lisa M Frenkel, R Leavitt Morrison, Trevon L Fuller, Maria Isabel Gouvêa, Maria de Lourdes Benamor Teixeira, Robert W Coombs, David E Shapiro, Mark Mirochnick, Roslyn Hennessey, Kyle Whitson, Nahida Chakhtoura, Esaú C João. Brief Report: Vaginal Viral Shedding With Undetectable Plasma HIV Viral Load in Pregnant Women Receiving 2 Different Antiretroviral Regimens: A Randomized Clinical Trial. Journal of acquired immune deficiency syndromes (1999). 2021 12; 88(4):361-365. doi: 10.1097/qai.0000000000002771. [PMID: 34369908]
  • Stephen I Walimbwa, Julian P Kaboggoza, Catriona Waitt, Pauline Byakika-Kibwika, Antonio D'Avolio, Mohammed Lamorde. An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR). Trials. 2021 Nov; 22(1):831. doi: 10.1186/s13063-021-05752-1. [PMID: 34814933]
  • Rocio Montejano, Lourdes Dominguez-Dominguez, Rosa de Miguel, David Rial-Crestelo, Andrés Esteban-Cantos, Paula Aranguren-Rivas, Mónica García-Álvarez, Belén Alejos, Otilia Bisbal, Mireia Santacreu-Guerrero, Asunción Hernando, Laura Bermejo-Plaza, Julen Cadiñanos, Mario Mayoral, Juan Miguel Castro, Victoria Moreno, Luz Martin-Carbonero, Berta Rodés, Rafael Delgado, Rafael Rubio, Federico Pulido, José Ramón Arribas. Detection of archived lamivudine-associated resistance mutations in virologically suppressed, lamivudine-experienced HIV-infected adults by different genotyping techniques (GEN-PRO study). The Journal of antimicrobial chemotherapy. 2021 11; 76(12):3263-3271. doi: 10.1093/jac/dkab323. [PMID: 34459889]
  • Z C Lim, G S Hoo, J H Ang, C B Teng, L W Ang, C C Lee, Y S Leo, H L Law, O T Ng, C S Wong. Safety and effectiveness of switching to Abacavir/Lamivudine plus rilpivirine for maintenance therapy in virologically suppressed HIV-1 individuals in Singapore (SEALS). AIDS research and therapy. 2021 11; 18(1):80. doi: 10.1186/s12981-021-00402-7. [PMID: 34724931]
  • Claire Pressiat, Evelyne Dainguy, Jean-Marc Tréluyer, Caroline Yonaba, Saik Urien, François Eboua, Frantz Foissac, Désiré Lucien Dahourou, Naïm Bouazza, Karen Malateste, Sophie Desmonde, Alain Pruvost, Valériane Leroy, Déborah Hirt, The Monod Anrs Study Group. Comparison of three galenic forms of lamivudine in young West African children living with Human Immunodeficiency Virus. Antiviral therapy. 2021 11; 26(6-8):134-140. doi: 10.1177/13596535211058267. [PMID: 35485334]
  • Sorour Khayyatnejad Shoushtari, Khalid Zoghebi, Muhammad Imran Sajid, Rakesh Kumar Tiwari, Keykavous Parang. Hybrid Cyclic-Linear Cell-Penetrating Peptides Containing Alternative Positively Charged and Hydrophobic Residues as Molecular Transporters. Molecular pharmaceutics. 2021 10; 18(10):3909-3919. doi: 10.1021/acs.molpharmaceut.1c00594. [PMID: 34491768]
  • Wei-Chieh Huang, Chun-Kai Huang, Sung-Hsi Huang, Shu-Wen Lin, Shyh-Tyan Ou, Yi-Ting Chen, Ya-Wen Chen, Shu-Yuan Chang, Wen-Chun Liu, Hsin-Yun Sun, Chien-Ching Hung. Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi. 2021 Oct; 54(5):944-951. doi: 10.1016/j.jmii.2020.06.010. [PMID: 32675042]
  • Alexa Hollinger, Nadine Cueni, Catia Marzolini, Michael Dickenmann, Emmanuelle Landmann, Manuel Battegay, Aurélien Emmanuel Martinez, Martin Siegemund, Anne Leuppi-Taegtmeyer. Lactic acidosis and hyperlactatemia associated with lamivudine accumulation and sepsis in a kidney transplant recipient-a case report and review of the literature. AIDS research and therapy. 2021 09; 18(1):56. doi: 10.1186/s12981-021-00382-8. [PMID: 34481501]
  • Rajendra P Singh, Kimberly Adkison, Allen Wolstenholme, Judy Hopking, Brian Wynne. Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Abacavir/Dolutegravir/Lamivudine Combination Tablets in Healthy Japanese Study Participants. Clinical pharmacology in drug development. 2021 09; 10(9):985-993. doi: 10.1002/cpdd.996. [PMID: 34265164]
  • H Zhang, C Y Wang, W K Cao, H W Wang, S Tao. [Analysis of risk factors for drug resistant mutations in the reverse transcriptase region in chronic hepatitis B virus-infected patients]. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology. 2021 Aug; 29(8):771-775. doi: 10.3760/cma.j.cn501113-20201009-00543. [PMID: 34517459]
  • R E Akhigbe, M A Hamed, A O Aremu. HAART exacerbates testicular damage and impaired spermatogenesis in anti-Koch-treated rats via dysregulation of lactate transport and glutathione content. Reproductive toxicology (Elmsford, N.Y.). 2021 08; 103(?):96-107. doi: 10.1016/j.reprotox.2021.06.007. [PMID: 34118364]
  • Carolina Herrera, Julianne Lwanga, Ming Lee, Suna Mantori, Alieu Amara, Laura Else, Sujan Dilly Penchala, Deirdre Egan, Elizabeth Challenger, Laura Dickinson, Marta Boffito, Robin Shattock, Saye Khoo, Julie Fox. Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP). The Journal of antimicrobial chemotherapy. 2021 07; 76(8):2129-2136. doi: 10.1093/jac/dkab136. [PMID: 33993302]
  • Brian R Wood, Anton L Pozniak. Dosing lamivudine or emtricitabine in renal impairment: new data confirm it's time for updated guidance!. AIDS (London, England). 2021 07; 35(8):1305-1307. doi: 10.1097/qad.0000000000002903. [PMID: 34076616]
  • Karam Mounzer, Laurence Brunet, Christina M Wyatt, Jennifer S Fusco, Vani Vannappagari, Allan R Tenorio, Mark S Shaefer, Leigh Ragone, Ricky K Hsu, Gregory P Fusco. To dose-adjust or not to dose-adjust: lamivudine dose in kidney impairment. AIDS (London, England). 2021 07; 35(8):1201-1208. doi: 10.1097/qad.0000000000002871. [PMID: 33710017]
  • Vladimir Reinharz, Yuji Ishida, Masataka Tsuge, Karina Durso-Cain, Tje Lin Chung, Chise Tateno, Alan S Perelson, Susan L Uprichard, Kazuaki Chayama, Harel Dahari. Understanding Hepatitis B Virus Dynamics and the Antiviral Effect of Interferon Alpha Treatment in Humanized Chimeric Mice. Journal of virology. 2021 06; 95(14):e0049220. doi: 10.1128/jvi.00492-20. [PMID: 33910953]
  • Andrea Giacomelli, Federico Conti, Laura Pezzati, Letizia Oreni, Anna Lisa Ridolfo, Valentina Morena, Cecilia Bonazzetti, Gabriele Pagani, Tiziana Formenti, Massimo Galli, Stefano Rusconi. Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study. BMC infectious diseases. 2021 Jun; 21(1):595. doi: 10.1186/s12879-021-06304-3. [PMID: 34157984]
  • Santiago Jiménez de Ory, Carolina Beltrán-Pavez, Miguel Gutiérrez-López, María Del Mar Santos, Luis Prieto, Talía Sainz, Sara Guillen, David Aguilera-Alonso, Cristina Díez, Jose Ignacio Bernardino, María José Mellado, José Tomás Ramos, África Holguín, Marisa Navarro. Prevalence of M184V and K65R in proviral DNA from PBMCs in HIV-infected youths with lamivudine/emtricitabine exposure. The Journal of antimicrobial chemotherapy. 2021 06; 76(7):1886-1892. doi: 10.1093/jac/dkab080. [PMID: 33734374]
  • Juan M Tiraboschi, Jhon Rojas, Henrik Zetterberg, Kaj Blennow, Jordi Niubo, Johanna Gostner, Antonio Navarro-Alcaraz, Camila Piatti, Dietmar Fuchs, Magnus Gisslén, Raul Rigo-Bonnin, Esteban Martinez, Daniel Podzamczer. No Changes in Human Immunodeficiency Virus (HIV) Suppression and Inflammatory Markers in Cerebrospinal Fluid in Patients Randomly Switched to Dolutegravir Plus Lamivudine (Spanish HIV/AIDS Research Network, PreEC/RIS 62). The Journal of infectious diseases. 2021 06; 223(11):1928-1933. doi: 10.1093/infdis/jiaa645. [PMID: 33049035]
  • Gianmaria Baldin, Arturo Ciccullo, Francesca Lombardi, Anna D'Angelillo, Alex Dusina, Arianna Emiliozzi, Damiano Farinacci, Davide Moschese, Chiara Picarelli, Alberto Borghetti, Simona Di Giambenedetto. Short Communication: Comparing Lamivudine+Dolutegravir and Bictegravir/Emtricitabine/Tenofovir Alafenamide as Switch Strategies: Preliminary Results from Clinical Practice. AIDS research and human retroviruses. 2021 06; 37(6):429-432. doi: 10.1089/aid.2020.0219. [PMID: 33280486]
  • Jean-Michel Molina, Yazdan Yazdanpanah, Alejandro Afani Saud, Christopher Bettacchi, Carolina Chahin Anania, Edwin DeJesus, Stephanie Olsen Klopfer, Anjana Grandhi, Karen Eves, Michael N Robertson, Todd Correll, Carey Hwang, George J Hanna, Peter Sklar. Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial. The lancet. HIV. 2021 06; 8(6):e324-e333. doi: 10.1016/s2352-3018(21)00021-7. [PMID: 34000227]
  • Anaïs Mennecier, Chipepo Kankasa, Paulin Fao, Jean-Pierre Moles, Sabrina Eymard-Duvernay, Mwiya Mwiya, Dramane Kania, Catherine Chunda-Liyoka, Leticia Sakana, David Rutagwera, Souleymane Tassembedo, Maria Melany Wilfred-Tonga, Beatriz Mosqueira, Thorkild Tylleskär, Nicolas Nagot, Philippe Van de Perre. Design and challenges of a large HIV prevention clinical study on mother-to-child transmission: ANRS 12397 PROMISE-EPI study in Zambia and Burkina Faso. Contemporary clinical trials. 2021 06; 105(?):106402. doi: 10.1016/j.cct.2021.106402. [PMID: 33872801]
  • Hao Liao, Jie Wang, Yan Liu, Junhui Chen, Dongping Xu, Fengmin Lu. Letter to the Editor: Why Serum Hepatitis B Virus (HBV) DNA Has Higher Frequency of rtM204I/V Mutation Than Serum HBV RNA in the Same Individual?. Hepatology (Baltimore, Md.). 2021 05; 73(5):2075-2076. doi: 10.1002/hep.31514. [PMID: 32772386]
  • Maxensia Owor, Camlin Tierney, Lauren Ziemba, Renee Browning, John Moye, Bobbie Graham, Christina Reding, Diane Costello, Jennifer Norman, Lubbe Wiesner, Emma Hughes, Meghan E Whalen, Lynette Purdue, Blandina Theophil Mmbaga, Portia Kamthunzi, Rachel Kawalazira, Kusum Nathoo, Sarah Bradford, Anne Coletti, Francesca Aweeka, Philippa Musoke. Pharmacokinetics and Safety of Zidovudine, Lamivudine, and Lopinavir/Ritonavir in HIV-infected Children With Severe Acute Malnutrition in Sub-Saharan Africa: IMPAACT Protocol P1092. The Pediatric infectious disease journal. 2021 05; 40(5):446-452. doi: 10.1097/inf.0000000000003055. [PMID: 33464021]
  • Constance Delaugerre, Marie-Laure Nere, Sabrina Eymard-Duvernay, Alix Armero, Laura Ciaffi, Sinata Koulla-Shiro, Adrien Sawadogo, Ndaye Fatou Ngom Gueye, Cheik Tidiane Ndour, Mireille Mpoudi Ngolle, Ali Amara, Marie-Laure Chaix, Jacques Reynes. Deep sequencing analysis of M184V/I mutation at the switch and at the time of virological failure of boosted protease inhibitor plus lamivudine or boosted protease inhibitor maintenance strategy (substudy of the ANRS-MOBIDIP trial). The Journal of antimicrobial chemotherapy. 2021 04; 76(5):1286-1293. doi: 10.1093/jac/dkab002. [PMID: 33624081]
  • Prashanth Chowdary, Shraddha Shetty, John Booth, Muhammad Arslan Khurram, Magdi Yaqoob, Ismail Heyder Mohamed. Experience of SARS-CoV-2 infection in two kidney transplant recipients living with HIV-1 infection. Transplant infectious disease : an official journal of the Transplantation Society. 2021 Apr; 23(2):e13500. doi: 10.1111/tid.13500. [PMID: 33174284]
  • Jia-Juen Lin, Kuan-Yin Lin, Hung-Jen Tang, Shih-Ping Lin, Yi-Chien Lee, Chun-Eng Liu, Yu-Shan Huang, Ning-Chi Wang, Chia-Wen Li, Wen-Chien Ko, Hao-Jan Yang, Yuan-Ti Lee, Chien-Ching Hung. Hepatitis B virus seroprevalence among HIV-infected patients receiving combination antiretroviral therapy three decades after universal neonatal hepatitis B immunization program in Taiwan. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi. 2021 Apr; 54(2):228-237. doi: 10.1016/j.jmii.2019.10.005. [PMID: 31708481]
  • Mark Nelson, Alan Winston, Andrew Hill, Rosie Mngqibisa, Ayesha Bassa, Chloe Orkin, Mohammed Rassool, Anthony Rodgers, Valerie Teal, Sushma Kumar, Hedy Teppler. Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine. AIDS (London, England). 2021 04; 35(5):759-767. doi: 10.1097/qad.0000000000002804. [PMID: 33587439]
  • R N Dallocchio, A Dessì, A De Vito, G Delogu, P A Serra, G Madeddu. Early combination treatment with existing HIV antivirals: an effective treatment for COVID-19?. European review for medical and pharmacological sciences. 2021 Mar; 25(5):2435-2448. doi: 10.26355/eurrev_202103_25285. [PMID: 33755983]
  • David Rial-Crestelo, Rosa de Miguel, Rocío Montejano, Lourdes Dominguez-Dominguez, Paula Aranguren-Rivas, Andrés Esteban-Cantos, Otilia Bisbal, Mireia Santacreu-Guerrero, Mónica Garcia-Alvarez, Belén Alejos, Asunción Hernando, Laura Bermejo-Plaza, Julen Cadiñanos, Mario Mayoral, Juan Miguel Castro, Victoria Moreno, Luz Martin-Carbonero, Rafael Delgado, Rafael Rubio, Federico Pulido, José Ramón Arribas. Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study. The Journal of antimicrobial chemotherapy. 2021 02; 76(3):738-742. doi: 10.1093/jac/dkaa479. [PMID: 33200210]
  • F Ibrahim, A Samarawickrama, L Hamzah, R Vincent, Y Gilleece, L Waters, S Kegg, B Barbini, L Campbell, F A Post. Bone mineral density, kidney function, weight gain and insulin resistance in women who switch from TDF/FTC/NNRTI to ABC/3TC/DTG. HIV medicine. 2021 02; 22(2):83-91. doi: 10.1111/hiv.12961. [PMID: 32985122]
  • Qi Huang, Bin Zhou, Dawei Cai, Yuhua Zong, Yaobo Wu, Shi Liu, Alexandre Mercier, Haitao Guo, Jinlin Hou, Richard Colonno, Jian Sun. Rapid Turnover of Hepatitis B Virus Covalently Closed Circular DNA Indicated by Monitoring Emergence and Reversion of Signature-Mutation in Treated Chronic Hepatitis B Patients. Hepatology (Baltimore, Md.). 2021 01; 73(1):41-52. doi: 10.1002/hep.31240. [PMID: 32189364]
  • Li-Qin Sun, Jia-Ye Liu, Yun He, Yang Zhou, Liu-Mei Xu, Lu-Kun Zhang, Fang Zhao, Xiao-Ning Liu, Ying Song, Ting-Zhi Cao, Yi-Mei Tian, Man Rao, Hui Wang. Evolution of blood lipids and risk factors of dyslipidemia among people living with human immunodeficiency virus who had received first-line antiretroviral regimens for 3 years in Shenzhen. Chinese medical journal. 2020 Dec; 133(23):2808-2815. doi: 10.1097/cm9.0000000000001245. [PMID: 33273329]
  • Yi Dong, Meina Li, Shishu Zhu, Xue Gao, Pan Zhao. De novo combination antiviral therapy in e antigen-negative chronic hepatitis B virus-infected paediatric patients with advanced fibrosis. Journal of viral hepatitis. 2020 12; 27(12):1338-1343. doi: 10.1111/jvh.13372. [PMID: 32810891]
  • Sanjeev Kumar, Himanshu Batra, Swarandeep Singh, Himanshi Chawla, Ravinder Singh, Sanket Katpara, Abdul Wahid Hussain, Bimal Kumar Das, Rakesh Lodha, Sushil Kumar Kabra, Kalpana Luthra. Effect of combination antiretroviral therapy on human immunodeficiency virus 1 specific antibody responses in subtype-C infected children. The Journal of general virology. 2020 12; 101(12):1289-1299. doi: 10.1099/jgv.0.001480. [PMID: 32915123]
  • Minseok Albert Kim, Seung Up Kim, Dong Hyun Sinn, Jeong Won Jang, Young-Suk Lim, Sang Hoon Ahn, Jae-Jun Shim, Yeon Seok Seo, Yang Hyun Baek, Sang Gyune Kim, Young Seok Kim, Ji Hoon Kim, Won Hyeok Choe, Hyung Joon Yim, Hyun Woong Lee, Jung Hyun Kwon, Sung Won Lee, Jae Young Jang, Hwi Young Kim, Yewan Park, Gi-Ae Kim, Hyun Yang, Han Ah Lee, Myeongseok Koh, Young-Sun Lee, Minkoo Kim, Young Chang, Yoon Jun Kim, Jung-Hwan Yoon, Fabien Zoulim, Jeong-Hoon Lee. Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study. Gut. 2020 12; 69(12):2214-2222. doi: 10.1136/gutjnl-2019-320015. [PMID: 32209606]
  • L Ryom, A Cotter, R De Miguel, C Béguelin, D Podlekareva, J R Arribas, C Marzolini, Pgm Mallon, A Rauch, O Kirk, J M Molina, G Guaraldi, A Winston, S Bhagani, P Cinque, J D Kowalska, S Collins, M Battegay. 2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0. HIV medicine. 2020 11; 21(10):617-624. doi: 10.1111/hiv.12878. [PMID: 32885559]
  • Christian Eggers, Richard Hoetelmans, Stephanie Läer. Zidovudine and lamivudine reach higher concentrations in ventricular than in lumbar human cerebrospinal fluid. AIDS (London, England). 2020 11; 34(13):1883-1889. doi: 10.1097/qad.0000000000002626. [PMID: 32694416]
  • Lifen Wang, Bingying Xie, Quan Zheng, Lixia Xu, Zhiming Ye. Efficacy of entecavir in treating hepatitis B virus-associated membranous nephropathy. Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva. 2020 Nov; 112(11):843-849. doi: 10.17235/reed.2020.6762/2019. [PMID: 33054304]
  • Julia Del Amo, Rosa Polo, Santiago Moreno, Asunción Díaz, Esteban Martínez, José Ramón Arribas, Inma Jarrín, Miguel A Hernán. Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy : A Cohort Study. Annals of internal medicine. 2020 10; 173(7):536-541. doi: 10.7326/m20-3689. [PMID: 32589451]
  • A Dravid, T P Betha, A K Sharma, R Gawali, U Mahajan, M Kulkarni, C Saraf, S Kore, M Dravid, N Rathod. Efficacy and safety of a single-tablet regimen containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg and efavirenz 400 mg as a switch strategy in virologically suppressed HIV-1-infected subjects on nonnucleoside reverse transcriptase inhibitor-containing first-line antiretroviral therapy in Pune, India. HIV medicine. 2020 10; 21(9):578-587. doi: 10.1111/hiv.12912. [PMID: 33021066]
  • Mangesh D Godbole, Prafulla M Sabale, Vijay B Mathur. Development of lamivudine liposomes by three-level factorial design approach for optimum entrapment and enhancing tissue targeting. Journal of microencapsulation. 2020 Sep; 37(6):431-444. doi: 10.1080/02652048.2020.1778806. [PMID: 32543317]
  • Weimin Wang, Nathan Smith, Edward Makarov, Yimin Sun, Catherine L Gebhart, Murali Ganesan, Natalia A Osna, Howard E Gendelman, Benson J Edagwa, Larisa Y Poluektova. A long-acting 3TC ProTide nanoformulation suppresses HBV replication in humanized mice. Nanomedicine : nanotechnology, biology, and medicine. 2020 08; 28(?):102185. doi: 10.1016/j.nano.2020.102185. [PMID: 32217146]
  • Rong Chen, Jun Chen, Jingna Xun, Zhiliang Hu, Qiong Huang, Renfang Zhang, Corky Steinhart, Yinzhong Shen, Li Liu, Hongzhou Lu. Pharmacogenomics and pharmacokinetics of efavirenz 400 or 600 mg in 184 treatment-naive HIV-infected patients in China. Pharmacogenomics. 2020 08; 21(13):945-956. doi: 10.2217/pgs-2019-0169. [PMID: 32838647]
  • Nicolas Margot, Renee Ram, Ian McNicholl, Richard Haubrich, Christian Callebaut. Differential detection of M184V/I between plasma historical HIV genotypes and HIV proviral DNA from PBMCs. The Journal of antimicrobial chemotherapy. 2020 08; 75(8):2249-2252. doi: 10.1093/jac/dkaa146. [PMID: 32413134]
  • Stuart Astbury, Marcia Maria Costa Nunes Soares, Emmanuel Peprah, Barnabas King, Ana Carolina Gomes Jardim, Jacqueline Farinha Shimizu, Paywast Jalal, Chiman H Saeed, Furat T Sabeer, William L Irving, Alexander W Tarr, C Patrick McClure. Nanopore sequencing from extraction-free direct PCR of dried serum spots for portable hepatitis B virus drug-resistance typing. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2020 08; 129(?):104483. doi: 10.1016/j.jcv.2020.104483. [PMID: 32544862]
  • Wu Menghua, Zheng Xin, Liu Jianwei, Zhang Yu, Yao Qinwei. Case report: one case of coronavirus disease 2019 (COVID-19) in a patient co-infected by HIV with a normal CD4+ T cell count. AIDS research and therapy. 2020 07; 17(1):46. doi: 10.1186/s12981-020-00301-3. [PMID: 32703286]
  • Eisuke Adachi, Makoto Saito, Kazuhiko Ikeuchi, Tokio Hoshina, Hiroshi Yotsuyanagi. Cases of coronavirus disease-2019 in HIV-infected transgender women. AIDS (London, England). 2020 07; 34(9):1435-1436. doi: 10.1097/qad.0000000000002573. [PMID: 32590441]
  • Hyun Young Woo, Jun Yong Park, Si Hyun Bae, Chang Wook Kim, Jae Young Jang, Won Young Tak, Dong Joon Kim, In Hee Kim, Jeong Heo, Sang Hoon Ahn. Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response. Clinical and molecular hepatology. 2020 07; 26(3):352-363. doi: 10.3350/cmh.2019.0044n. [PMID: 32460460]
  • Louis Nyende, Robert Kalyesubula, Emmanuel Sekasanvu, Pauline Byakika-Kibwika. Prevalence of renal dysfunction among HIV infected patients receiving Tenofovir at Mulago: a cross-sectional study. BMC nephrology. 2020 06; 21(1):232. doi: 10.1186/s12882-020-01873-y. [PMID: 32571236]
  • Julian Hercun, Christopher Koh, Theo Heller. Hepatitis Delta: Prevalence, Natural History, and Treatment Options. Gastroenterology clinics of North America. 2020 06; 49(2):239-252. doi: 10.1016/j.gtc.2020.01.004. [PMID: 32389361]
  • Chloe Orkin, Edwin DeJesus, Paul E Sax, Jose R Arribas, Samir K Gupta, Claudia Martorell, Jeffrey L Stephens, Hans-Jurgen Stellbrink, David Wohl, Franco Maggiolo, Melanie A Thompson, Daniel Podzamczer, Debbie Hagins, Jason A Flamm, Cynthia Brinson, Amanda Clarke, Hailin Huang, Rima Acosta, Diana M Brainard, Sean E Collins, Hal Martin. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. The lancet. HIV. 2020 06; 7(6):e389-e400. doi: 10.1016/s2352-3018(20)30099-0. [PMID: 32504574]
  • Charlotte Charpentier, Gilles Peytavin, François Raffi, Charles Burdet, Roland Landman, Minh P Lê, Christine Katlama, Gilles Collin, Aida Benalycherif, André Cabie, France Mentré, Yazdan Yazdanpanah, Diane Descamps, Véronique Joly. Pharmacovirological analyses of blood and male genital compartment in patients receiving dolutegravir + lamivudine dual therapy as a switch strategy (ANRS 167 LAMIDOL trial). The Journal of antimicrobial chemotherapy. 2020 06; 75(6):1611-1617. doi: 10.1093/jac/dkaa035. [PMID: 32091102]
  • Jessica Hernández-Pineda, Helgi Helene Jung-Cook, Norah Lucky Katende-Kyenda, Norma Galindo-Sevilla, Mauricio Domínguez-Castro, José Romo-Yañéz, Alicia Ramírez-Ramírez, Claudine Irles, Ricardo Figueroa-Damián. Assessment of lamivudine, zidovudine, lopinavir, and ritonavir plasma levels in HIV-positive pregnant women: Drug monitoring application to improve patient safety. Medicine. 2020 May; 99(22):e20487. doi: 10.1097/md.0000000000020487. [PMID: 32481459]
  • Esaú C João, R Leavitt Morrison, David E Shapiro, Nahida Chakhtoura, Maria Isabel S Gouvèa, Maria de Lourdes B Teixeira, Trevon L Fuller, Blandina T Mmbaga, James S Ngocho, Boniface N Njau, Avy Violari, Ruth Mathiba, Zaakirah Essack, Jose Henrique S Pilotto, Luis Felipe Moreira, Maria Jose Rolon, Pedro Cahn, Sinart Prommas, Timothy R Cressey, Kulkanya Chokephaibulkit, Peerawong Werarak, Lauren Laimon, Roslyn Hennessy, Lisa M Frenkel, Patricia Anthony, Brookie M Best, George K Siberry, Mark Mirochnick. Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial. The lancet. HIV. 2020 05; 7(5):e322-e331. doi: 10.1016/s2352-3018(20)30038-2. [PMID: 32386720]
  • Rosa De Miguel, David Rial-Crestelo, Lourdes Dominguez-Dominguez, Rocío Montejano, Andrés Esteban-Cantos, Paula Aranguren-Rivas, Natalia Stella-Ascariz, Otilia Bisbal, Laura Bermejo-Plaza, Mónica Garcia-Alvarez, Belén Alejos, Asunción Hernando, Mireia Santacreu-Guerrero, Julen Cadiñanos, Mario Mayoral, Juan Miguel Castro, Victoria Moreno, Luz Martin-Carbonero, Rafael Delgado, Rafael Rubio, Federico Pulido, José Ramón Arribas. Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO). EBioMedicine. 2020 May; 55(?):102779. doi: 10.1016/j.ebiom.2020.102779. [PMID: 32408111]
  • Ya-Wen Yang, Meng-Kun Tsai, Ching-Yao Yang, Chih-Yuan Lee, Bor-Luen Chiang, Hong-Shiee Lai. Telbivudine for renal transplant recipients with chronic hepatitis B infection: a randomized controlled trial with early termination. Clinical and experimental nephrology. 2020 May; 24(5):474-482. doi: 10.1007/s10157-020-01850-7. [PMID: 32219622]
  • Joseph Eron, Chien-Ching Hung, Jean-Guy Baril, Jihad Slim, Vicenç Falcó, Johannes Bogner, Franco Maggiolo, Anthony Mills, Jörg Sievers, Choy Y Man, Rimgaile Urbaityte, Mark Underwood, Allan R Tenorio, Keith A Pappa, Brian Wynne, Justin Koteff, Martin Gartland, Kimberly Y Smith, Michael Aboud. Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis. Journal of acquired immune deficiency syndromes (1999). 2020 05; 84(1):60-65. doi: 10.1097/qai.0000000000002302. [PMID: 31977595]
  • Kazumoto Murata, Senko Tsukuda, Futoshi Suizu, Akihiro Kimura, Masaya Sugiyama, Koichi Watashi, Masayuki Noguchi, Masashi Mizokami. Immunomodulatory Mechanism of Acyclic Nucleoside Phosphates in Treatment of Hepatitis B Virus Infection. Hepatology (Baltimore, Md.). 2020 05; 71(5):1533-1545. doi: 10.1002/hep.30956. [PMID: 31529730]
  • Aude Jary, Anne-Geneviève Marcelin, Charlotte Charpentier, Marc Wirden, Minh P Lê, Gilles Peytavin, Diane Descamps, Vincent Calvez. M184V/I does not impact the efficacy of abacavir/lamivudine/dolutegravir use as switch therapy in virologically suppressed patients. The Journal of antimicrobial chemotherapy. 2020 05; 75(5):1290-1293. doi: 10.1093/jac/dkaa019. [PMID: 32065630]
  • Laurent Hocqueloux, Camélia Gubavu, Thierry Prazuck, Barbara De Dieuleveult, Jérôme Guinard, Aymeric Sève, Catherine Mille, Elise Gardiennet, Pauline Lopez, Christine Rouzioux, Sandrine Lefeuvre, Véronique Avettand-Fènoël. Genital Human Immunodeficiency Virus-1 RNA and DNA Shedding in Virologically Suppressed Individuals Switching From Triple- to Dual- or Monotherapy: Pooled Results From 2 Randomized, Controlled Trials. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020 04; 70(9):1973-1979. doi: 10.1093/cid/ciz511. [PMID: 31350995]
  • Guiyu Li, Jiyong Lin, Cen Jiang, Quansheng Feng, Li Wen. Trends in chronic hepatitis B treatment-related research from 1973 to 2018: a bibliometric and visual analysis. The Journal of international medical research. 2020 Apr; 48(4):300060519893234. doi: 10.1177/0300060519893234. [PMID: 31878813]
  • Xiuhui Li, Hongyan Li, Chuanyun Li, Wei Xia, Ang Li, Weihua Li. Traditional Chinese Medicine Can Improve the Immune Reconstruction of HIV/AIDS Patients. AIDS research and human retroviruses. 2020 04; 36(4):258-259. doi: 10.1089/aid.2019.0274. [PMID: 31958968]
  • Xinzhu Wang, Marta Boffito, Laura Dickinson, Emmanouil Bagkeris, Saye Khoo, Frank A Post, Jaime Vera, Ian Williams, Amalia Ndoutoumou, Jane Anderson, Patrick Mallon, Myra McClure, Alan Winston, Caroline Sabin. Plasma nucleotide reverse transcriptase inhibitor concentration and their associations with liver and renal parameters in people living with HIV. AIDS (London, England). 2020 04; 34(5):790-793. doi: 10.1097/qad.0000000000002479. [PMID: 32167992]
  • Chloe Orkin, Jean-Michel Molina, Johan Lombaard, Edwin DeJesus, Anthony Rodgers, Sushma Kumar, Elizabeth Martin, George Hanna, Carey Hwang. Once-daily Doravirine in Human Immunodeficiency Virus Type 1-Infected, Antiretroviral-naive Adults: An Integrated Efficacy Analysis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020 03; 70(7):1344-1352. doi: 10.1093/cid/ciz424. [PMID: 31121015]
  • Marta Fernández-González, José A García, Sergio Padilla, Javier García-Abellán, Vanesa Agulló, Félix Gutiérrez, Mar Masiá. Rectal and seminal HIV-1 RNA decay towards virological suppression in infected MSM initiating dolutegravir/abacavir/lamivudine. The Journal of antimicrobial chemotherapy. 2020 03; 75(3):668-674. doi: 10.1093/jac/dkz482. [PMID: 31769846]
  • Akiko Fukuda, Takako Nagao, Tomomi Kitaichi, Ichiro Koga, Akihiro Kobayashi, Toshiyuki Miura. Safety analysis of Lexiva tablets 700 (fosamprenavir calcium hydrate) in post-marketing surveillance in Japan. Current medical research and opinion. 2020 03; 36(3):455-464. doi: 10.1080/03007995.2019.1700495. [PMID: 31794279]
  • Matthew M Hernandez, Audrey Fahrny, Anitha Jayaprakash, Gustavo Gers-Huber, Marsha Dillon-White, Annette Audigé, Lubbertus C F Mulder, Ravi Sachidanandam, Roberto F Speck, Viviana Simon. Impact of Suboptimal APOBEC3G Neutralization on the Emergence of HIV Drug Resistance in Humanized Mice. Journal of virology. 2020 02; 94(5):. doi: 10.1128/jvi.01543-19. [PMID: 31801862]
  • Ahmet Alper Öztürk, İrem Namlı, Kadri Güleç, Şennur Görgülü. Design of Lamivudine Loaded Nanoparticles for Oral Application by Nano Spray Drying Method: A New Approach to use an Antiretroviral Drug for Lung Cancer Treatment. Combinatorial chemistry & high throughput screening. 2020; 23(10):1064-1079. doi: 10.2174/1386207323666200325155020. [PMID: 32209039]